Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

@article{Munster2009ClinicalAB,
  title={Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC},
  author={P. Munster and D. Marchion and E. Biçaku and M. Lacevic and J. Kim and B. Centeno and A. Daud and Anthony M Neuger and S. Minton and D. Sullivan},
  journal={Clinical Cancer Research},
  year={2009},
  volume={15},
  pages={2488 - 2496}
}
  • P. Munster, D. Marchion, +7 authors D. Sullivan
  • Published 2009
  • Biology, Medicine
  • Clinical Cancer Research
  • Purpose: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Experimental Design: A phase I dose escalation of valproic acid given on days 1 to 3 followed by epirubicin (day 3) was followed by a dose expansion of valproic acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC100). Pharmacodynamic and pharmacokinetic studies entailed valproic acid and epirubicin plasma… CONTINUE READING
    134 Citations
    Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
    • 138
    A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
    • 16
    Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    • R. Aggarwal, S. Thomas, +11 authors P. Munster
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2017
    • 40
    Spontaneous Cancer
    • PDF
    A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    • 279
    • PDF

    References

    SHOWING 1-10 OF 76 REFERENCES
    Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    • P. Münster, D. Marchion, +11 authors A. Daud
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2007
    • 198
    Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    • O. O’Connor, M. Heaney, +12 authors W. Kelly
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2006
    • 403